Science
We Have a New AbbVie Price Target After Our Previous One Was Reached
Here's our fresh take on the shares.
Is This Pullback in Knowles Corp a Buying Opportunity?
Patient investors could go long KN at current levels.
Beaten-Down Biogen Could Finally Be Reaching an 'Interesting' Level
The shares have been cut in half over the last six months.
'A' Is for Buying: Agilent Is Resuming Its Uptrend
Here's how traders can play the stock.
Intuitive Surgical Is Rallying Ahead of Earnings
Traders could go long ISRG at current levels.
Medtronic Needs to Rebase Before Being Attractive Again
Stand aside and let things "shake out".
BNGO! Looks Like Bionano Genomics Could Be a Winner
Here's why the current weakness in Bionano Genomics could be a buying opportunity.
Intellia Therapeutics Busts Out of Resistance on Positive Trial News
The news sent shares of the genome editing company skyward after the stock had been basing for months.
Halfway Home and This Portfolio of Lovable Losers Keeps Delivering
The 2021 Tax Loss Selling Recovery Portfolio didn't do much in April but is soundly beating the market six months after inception.
CRISPR Therapeutics Could Suffer Further Steep Losses
Let's look over the charts and indicators.